Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far
Reviewed 20 sourcesPublished by PepVault
Berobenatide (PF-08653944, MET-097i) is Pfizer's monthly GLP-1 shot in phase 3: how it lasts, every phase 2 number, all 24 trials, and when results are due.

- Last reviewed
- Sources
- 20
- Questions
- 7
- Compounds
- 3
The short answer
Berobenatide (PF-08653944, first called MET-097i) is Pfizer's experimental GLP-1 shot, built to last long enough for one injection a month. It is approved nowhere. In phase 2, weight fell up to 14.1% more than on placebo after 28 weekly shots, and 12.3% more when people moved to monthly shots. The first phase 3 trial, VESPER-4, ends its main measurement in September 2027 (registry estimate).
Evidence: Early: company-run phase 2 trials in people (VESPER-1 with results posted on ClinicalTrials.gov; VESPER-2 and VESPER-3 from Pfizer's releases), no journal paper yet, and phase 3 under way with no result. Approved nowhere.

What is berobenatide?
Berobenatide is an experimental weight-loss injection, a GLP-1 receptor agonist: a drug that switches on the body's receptor for GLP-1, the gut hormone that helps set appetite, the same receptor Wegovy and Zepbound act on. It was made by Metsera, a New York biotech, as MET-097i (MET097 in the trial records). Pfizer bought Metsera and now develops it as PF-08653944, shortened to PF'3944. Berobenatide is its generic name, the international nonproprietary name (INN) the World Health Organization proposed in 2025 and recommended in 202620; Pfizer has used it since June 20267.
Pfizer won it after a bidding contest. Novo Nordisk, the maker of Wegovy, made a rival offer, which Metsera disclosed on October 30, 2025, and Pfizer raised its own from $47.50 to $65.60 a share in cash, plus up to $20.65 more tied to milestones23. The deal closed on November 13, 2025, at an enterprise value of about $7.0 billion1.
As of November 20, 2026, berobenatide is approved nowhere and given only inside Pfizer's clinical trials. No result has been published in a journal yet; the numbers below come from the trial registry and the two companies' own reports.

How does berobenatide work?
Like every GLP-1 drug, it lowers appetite, makes a meal feel filling sooner and slows how fast the stomach empties. Two design choices set it apart4.
- It is fully biased. When a GLP-1 receptor is switched on it sends a signal (through a messenger called cAMP) and also pulls in a protein called beta-arrestin, which dulls the receptor and draws it into the cell. Berobenatide is built to send the signal without pulling in beta-arrestin, so the receptor keeps working over time4.
- It carries a lipid tail. The peptide is a reworked exendin-4, the Gila monster peptide behind the older drug exenatide. Metsera's HALO method fixes a fatty chain to its tail end, so it rides on albumin, a blood protein, and the body clears it slowly420.
The result is a long half-life, the time the body takes to clear half a dose: about 15 to 16 days in Metsera's first human trial4, against about one week for semaglutide and five to six days for tirzepatide1819. Pfizer says a monthly dose fits in a 0.5 mL injection7.
Why does monthly dosing matter?
A monthly shot means 12 injections a year instead of 52, and a missed week matters less. The long half-life also means the drug lingers. In Metsera's first trial, people who took five weekly 1.2 mg shots were 7.5% lighter on day 36, 8.1% on day 57, and still 7.5% lighter on day 85, eight weeks after the last shot; the placebo group's change was under 1% throughout4. That was a small, short trial, but it is the behaviour a monthly drug needs.
In the trials, people start weekly and then move to monthly. VESPER-3 gave weekly shots for 12 weeks, with up to two steps up, then one shot a month: 3.2 mg or 4.8 mg in the two schedules Pfizer chose for phase 3, where it planned to add a higher 9.6 mg monthly dose6. These are trial doses, not a regimen to follow. Phase 3 also keeps a weekly version, so berobenatide may come both ways.
PepVault can hold a dose every 28 days as easily as a weekly one, and the reminder comes on the day it falls due, so a monthly shot is not lost between months. Set reminders in PepVault
How much weight did people lose on berobenatide?
Up to about 14% more than placebo in 28 weeks, with no plateau yet. VESPER-1 gave 239 adults a weekly shot at a fixed dose from the first week, with no slow climb, for 28 weeks; on 1.2 mg, weight fell 12.5% while the placebo group gained 1.7%8. Each figure below is the change while people stayed on treatment (the efficacy measure); counting everyone who started, including those who stopped (the treatment-policy measure), the numbers run lower, as VESPER-3's second row shows.
| Trial | People | Weeks | Dosing | Weight change | Beyond placebo |
|---|---|---|---|---|---|
| Phase 1/2, part C49 | 120 | 12 | Weekly, 0.6 to 1.2 mg | Not reported | 7.2% to 11.3% (preliminary) |
| VESPER-158 | 239 | 28 | Weekly, 0.4 to 1.2 mg, no step-up | -6.4% to -12.5% (placebo +1.7%) | 8.1 to 14.1 points |
| VESPER-1 extension7 | People moved from placebo | 32 on the drug | Weekly, 2.4 mg | -15.9% (average, no placebo group) | Not applicable |
| VESPER-3, while on treatment611 | 268 | 28 | Weekly 12 weeks, then monthly | Not reported | 10.0 and 12.3 points |
| VESPER-3, counting everyone6 | 268 | 28 | Weekly 12 weeks, then monthly | Not reported | 8.4 and 10.5 points |
The VESPER-3 pairs are the two monthly schedules that went into phase 3, and Pfizer reports that weight was still falling at week 286. In VESPER-2, in 133 people with type 2 diabetes, HbA1c (the three-month blood sugar average) fell 2.2 points on 1.6 mg weekly at 28 weeks, against 0.2 on placebo710. These results cover 28 weeks (VESPER-3 ran on to week 64 and ended in October 2026, with those numbers not yet released11); the approved weekly drugs were measured over 68 to 72 weeks, so a fair comparison waits for phase 3.
What side effects did berobenatide cause in trials?
The usual GLP-1 ones, in the stomach and gut, mostly mild or moderate6. VESPER-1 started people on their full dose with no step-up. On 1.2 mg, 24 of 48 people reported nausea at some point, against 13 of 48 on placebo; vomiting 12 against 6; diarrhea 11 against 58. Only 2 of the 239 people stopped treatment because of side effects5.
Stepping up helped. In VESPER-3's first 12 weeks, the schedule that climbed 0.4, 0.8 then 1.2 mg had about 13 percentage points more nausea than placebo, 11 more vomiting, and no more diarrhea5. Across the two phase 3 schedules, five people stopped for side effects in the weekly weeks and five in the monthly weeks, of about 108; none stopped on placebo6.
When to get help On any GLP-1 drug, severe stomach pain that does not ease, sometimes reaching the back, or vomiting that stops you keeping fluids down is a reason to call your clinician the same day18.
Which berobenatide trials are in the registry?
Twenty-four records name it under one of its names as of November 20, 2026, all sponsored by Pfizer or by Metsera as Pfizer's subsidiary17. Pfizer had said it would run 10 phase 3 trials in 20266; the registry now lists 13. Dates are primary completion, per ClinicalTrials.gov: when the main measurement ends, not when results come out. "Est." marks the sponsor's estimate.
| Phase 3 trial | Who | People | Primary completion | Status |
|---|---|---|---|---|
| VESPER-4, weekly (NCT07311850)12 | Obesity or overweight, no diabetes | 3,578 | Sep 2027 (est.) | Active, not recruiting |
| VESPER-5, weekly (NCT07400653)13 | With type 2 diabetes | 1,078 | Oct 2027 (est.) | Active, not recruiting |
| VESPER-6, monthly (NCT07595549)14 | Obesity or overweight | 954 (planned) | May 2028 (est.) | Recruiting |
| VESPER-SWITCH, monthly (NCT07845500)15 | Now on weekly semaglutide or tirzepatide | 660 (planned) | Feb 2028 (est.) | Recruiting |
| Weekly, China (NCT07792954) | Chinese adults | 300 (planned) | Mar 2028 (est.) | Recruiting |
| Monthly, China (NCT07874633) | Chinese adults | 432 (planned) | Jun 2028 (est.) | Recruiting |
| VESPER-JW, weekly (NCT07794761) | Adults in Japan | 180 (planned) | Mar 2029 (est.) | Recruiting |
| VESPER-JM, monthly (NCT07794774) | Adults in Japan | 197 (planned) | Feb 2029 (est.) | Recruiting |
| VESPER-OSA 1, monthly (NCT07823608) | Sleep apnea, using a breathing machine | 258 (planned) | Apr 2028 (est.) | Recruiting |
| VESPER-OSA 2, monthly (NCT07881757) | Sleep apnea, no breathing machine | 258 (planned) | Jun 2028 (est.) | Recruiting |
| VESPER-OA 1, monthly (NCT07919678) | Knee osteoarthritis | 656 (planned) | Aug 2028 (est.) | Recruiting |
| VESPER-OA 2, weekly (NCT07915609) | Knee osteoarthritis | 756 (planned) | Aug 2028 (est.) | Recruiting |
| VESPER-SUI (NCT07932925) | Women with stress urine leakage | 900 (planned) | Oct 2028 (est.) | Recruiting |
| Earlier or smaller trial | Phase | People | Primary completion | Status |
|---|---|---|---|---|
| First human trial (NCT06857617)9 | 1/2 | 120 | Jan 2025 | Completed |
| VESPER-1 (NCT06712836)8 | 2b | 239 | Jul 2025 | Completed, results posted |
| VESPER-2, type 2 diabetes (NCT06897202)10 | 2b | 133 | Dec 2025 | Completed |
| VESPER-3, weekly then monthly (NCT06973720)11 | 2b | 268 | Dec 2025 | Completed |
| With the amylin drug MET-233i (NCT06924320) | 1/2 | 201 | Sep 2026 | Completed |
| SOLIS-1, with amylin drug PF-08653945 (NCT07575932)16 | 2b | 940 | Aug 2027 (est.) | Active, not recruiting |
| Injection sites (NCT07400679) | 1 | 48 | Jul 2026 | Completed |
| Stomach emptying (NCT07508241) | 1 | 22 | Jan 2027 (est.) | Active, not recruiting |
| Single dose, China (NCT07845513) | 1 | 11 | Feb 2027 (est.) | Active, not recruiting |
| Delivery devices (NCT07876531) | 1 | 144 (planned) | Apr 2027 (est.) | Recruiting |
| Liver function (NCT07519135) | 1 | 26 (planned) | Jul 2027 (est.) | Recruiting |
The weight trials measure the change in body weight at 64 weeks (VESPER-4 and -5) or 72 weeks (VESPER-6)121314. VESPER-SWITCH asks whether people who already lost weight on a weekly shot keep it off after moving to monthly berobenatide, measured at 32 weeks15. The amylin pairing matters too: amylin is a second gut hormone that adds fullness, and Pfizer plans berobenatide as the base of combination shots616.
When will berobenatide's next results come out?
The first phase 3 answers can come from late 2027. VESPER-4, the large weekly trial, has an estimated primary completion of September 21, 2027, and VESPER-5 of October 12, 2027, both Pfizer's estimates on ClinicalTrials.gov1213; results usually follow some weeks later. SOLIS-1, the amylin combination, finishes its main measurement in August 2027 (registry estimate)16. The monthly phase 3 answer, VESPER-6, follows, estimated for May 202814.
Has a phase 3 trial reported yet? Not as of November 20, 2026. Pfizer has given no filing or approval date: its June 2026 release names none7. This page is updated when the first result lands.
If you take a weekly GLP-1 today, PepVault keeps your weight log and trend beside your doses, so any later switch, to a monthly shot or anything else, starts from your own numbers. Track your weight in PepVault
Sources
- Pfizer. Pfizer completes acquisition of Metsera. November 13, 2025. pfizer.com
- Metsera, Inc. Form 8-K: receipt of an unsolicited proposal from Novo Nordisk. October 30, 2025. sec.gov
- Metsera, Inc. Form 8-K: Amendment No. 1 to the Agreement and Plan of Merger with Pfizer Inc. November 10, 2025. sec.gov
- Metsera, Inc. Annual report on Form 10-K for the year ended December 31, 2024 (MET-097i, the HALO platform and the phase 1/2 trial). March 26, 2025. sec.gov
- Metsera. Positive phase 2b results for MET-097i: VESPER-1 topline and VESPER-3 interim tolerability (Form 8-K, Exhibit 99.1). September 29, 2025. sec.gov
- Pfizer. Pfizer's ultra-long-acting injectable GLP-1 RA shows robust and continued weight loss with monthly dosing in phase 2b trial (VESPER-3). February 3, 2026. pfizer.com
- Pfizer. Robust phase 2b efficacy and favorable tolerability support monthly dosing for Pfizer's GLP-1 RA berobenatide. June 6, 2026. pfizer.com
- ClinicalTrials.gov. NCT06712836: VESPER-1, once-weekly MET097 (berobenatide) in adults with obesity or overweight, posted results. Pfizer. clinicaltrials.gov
- ClinicalTrials.gov. NCT06857617: phase 1/2 study of MET097 in adults with obesity or overweight. Metsera, a wholly owned subsidiary of Pfizer. clinicaltrials.gov
- ClinicalTrials.gov. NCT06897202: VESPER-2, once-weekly MET097 in adults with obesity or overweight and type 2 diabetes. Pfizer. clinicaltrials.gov
- ClinicalTrials.gov. NCT06973720: VESPER-3, once-weekly switching to once-monthly MET097. Pfizer. clinicaltrials.gov
- ClinicalTrials.gov. NCT07311850: VESPER-4, MET097 (PF-08653944) once weekly in people with overweight or obesity. Pfizer. clinicaltrials.gov
- ClinicalTrials.gov. NCT07400653: VESPER-5, PF-08653944 in people with overweight or obesity and type 2 diabetes. Pfizer. clinicaltrials.gov
- ClinicalTrials.gov. NCT07595549: VESPER-6, once-monthly berobenatide (PF-08653944) in adults with overweight or obesity. Pfizer. clinicaltrials.gov
- ClinicalTrials.gov. NCT07845500: VESPER-SWITCH, switching to monthly berobenatide in adults on weekly semaglutide or tirzepatide. Pfizer. clinicaltrials.gov
- ClinicalTrials.gov. NCT07575932: SOLIS-1, PF-08653945 and PF-08653944 alone or in combination. Pfizer. clinicaltrials.gov
- ClinicalTrials.gov. All studies naming berobenatide, PF-08653944 or MET097, read November 20, 2026. clinicaltrials.gov
- Wegovy (semaglutide) prescribing information. Novo Nordisk. DailyMed. dailymed.nlm.nih.gov
- Zepbound (tirzepatide) prescribing information. Eli Lilly. DailyMed. dailymed.nlm.nih.gov
- World Health Organization. Recommended INN: List 95 (berobenatide; first proposed in List 133, 2025). WHO Drug Information, Vol. 40, No. 1, 2026. cdn.who.int
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.